...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Parkinsonism & related disorders >Tolerability and efficacy of switching from oral selegiline to Zydis selegiline in patients with Parkinson's disease.
【24h】

Tolerability and efficacy of switching from oral selegiline to Zydis selegiline in patients with Parkinson's disease.

机译：帕金森氏病患者从口服司来吉兰转为Zydis司吉兰的耐受性和疗效。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Selegiline is a monoamine-B specific inhibitor used to treat Parkinson's disease. A Zydis sublingual preparation has more efficient absorption and less first pass amphetamine metabolites. We conducted an open label oral to Zydis switch study to evaluate tolerability of rapid switch, and relative efficacy, in 48 subjects from 5 sites. Overall patients preferred the Zydis preparation. Per clinician global impressions, fluctuations improved and the "on" UPDRS part II scores improved. Total UPDRS and measures of fatigue and sleep were unchanged. Adverse events were mild. Patients generally preferred the Zydis selegiline preparation but the modest difference is of unclear clinical significance given the open label nature of the trial.
机译：司来吉兰是用于治疗帕金森氏病的单胺B特异性抑制剂。 Zydis舌下制剂的吸收效率更高，首过苯丙胺代谢产物更少。我们对Zydis转换进行了开放标签的口服研究，以评估来自5个地点的48位受试者的快速转换耐受性和相对功效。总体而言，患者更喜欢Zydis制剂。根据临床医生的整体印象，波动得到改善，UPDRS第二部分“上”的分数得到改善。总体UPDRS和疲劳和睡眠指标未发生变化。不良事件轻微。患者通常更喜欢使用Zydis司来吉兰制剂，但鉴于试验的开放标签性质，这种适度的差异尚无明确的临床意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号